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ABSTRACT: Seven new caged xanthones, doitunggarcinones E-K (1-7), all as scalemic 25 
mixtures and 10 known compounds (8‒17), were isolated from the stem bark extract of 26 
Garcinia propinqua. The structures were elucidated on the basis of spectroscopic methods. 27 
The separation of the enantiomers of 1-6 was achieved by semi-preparative chiral HPLC. The 28 
absolute configuration of compound (+)-1 was determined by single-crystal X-ray 29 
crystallographic analysis using Cu Kα radiation. The absolute configurations of the other 30 
related compounds were determined from comparisons of their ECD spectra with that of 31 
compound (+)-1. Compounds (‒)-6 and 7 showed cytotoxicity against a colon cancer cell line 32 




















The Garcinia genus belongs to the Clusiaceae family, which is found mainly in tropical and 51 
subtropical countries. This genus is well known as a rich source of xanthones,1-10 caged 52 
xanthones,11-21 flavonoids,22 terpenoids,23 biphenyls,24-25 and benzophenones.26-30 Many of 53 
these compounds have a wide range of biological and pharmacological activities, including 54 
antimicrobial,29,31 antidepressant,29 anti-HIV,29,32 antibacterial,2,3,9,10,18,22 and cytotoxic 55 
activities.6,8,12-17,27,29 In a previous paper we reported the isolation of xanthones, caged 56 
xanthones, and rearranged benzophenones from the twig and root extracts of Garcinia 57 
propinqua collected from Doi Tung, Chiang Rai Province, Thailand.2,33 Herein, the isolation 58 
and identification of seven new caged xanthones, doitunggarcinones E-K (1‒7), as scalemic 59 
mixtures, together with 10 known compounds (8‒17) from the stem bark extract of G. 60 
propinqua are reported. The isolated compounds were also assayed for their cytotoxicities 61 
against a colon cancer cell line. 62 
RESULTS AND DISCUSSION 63 
A MeOH extract of the stem bark of G. propinqua was dissolved in H2O and partitioned with 64 
CH2Cl2 and EtOAc. A combination of the CH2Cl2 and EtOAc extracts was separated by 65 
chromatographic techniques resulting in the isolation of seven new caged xanthones (1‒7) 66 
together with 10 known  compounds, xerophenone A (8),34 doitunggarcinones A (9)2,35 and B 67 
(10),2,35 sampsonione B (11),36 7β-H-11-benzoyl-5α-hydroxy-6,6,10,10-tetramethyl-1-(3-68 
methyl-2-butenyl)tetracyclo[7.3.1.13,1103,7]tetradecane-2,12,14-trione (12),37 hypersampsone 69 
M (13),38 assiguxanthone A (14),39 cudraxanthone Q (15),40 10-O-methylmacluraxanthone 70 
(16),41 and 5-O-methylxanthone V1 (17).
12  71 
Compound 1 was obtained as a white solid (m.p. 183-185 °C) which showed a 72 
protonated molecular ion at m/z 527.2643 [M+H]+ (calcd for 527.2645) in the ESITOFMS 73 
corresponding to a molecular formula of C30H38O8. The UV spectrum showed absorption 74 
bands at λmax 219, 232, 239, 295, and 342 nm while the IR spectrum indicated the presence of 75 
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a hydroxy group at 3415 cm-1 and conjugated carbonyl group at 1639 cm-1. The presence of 76 
carbonyl group was confirmed by the 13C NMR resonance at δC 196.1 (C-9). Some of the 77 
NMR chemical shifts of compound 1 (Tables 1, 2, S1 and Figures S1-S7, Supporting 78 
Information) were similar to those of the 8,8a-dihydro caged xanthone, 1-O-methyl-8-79 
methoxy-8,8a-dihydrobractatin, isolated from the leaves of G. bracteata.15 The core structure 80 
of 1 was deduced from the following NMR spectroscopic data which show resonances for an 81 
H-bonded hydroxy proton [δH 12.39 (1H, s, OH-1)], an isolated aromatic proton [δH 6.08 (1H, 82 
s, H-2)/δC 93.4], three methine protons [δH 4.00 (1H, dd, J = 4.4, 2.6 Hz, H-8)/δC 79.3, δH 83 
3.01 (1H, d, J = 4.4 Hz, H-8a)/δC 48.6 and  δH 2.41 (1H, m, H-7)/δC 31.6], a caged unit, ‒84 
OC(Me)2CHCH2C‒, [δH 2.26 (1H, dd, J = 15.2, 5.2 Hz, H-21a)/δC 25.1, δH 2.22 (1H, d, J = 85 
10.2 Hz, H-22)/δC 43.2, δH 1.41 (1H, dd, J = 15.2, 10.2 Hz, H-21b)/δC 25.1, δH 1.33 (3H, s, 86 
H3-24)/δC 30.2, and δH 1.26 (3H, s, H3-25)/δC 27.2], two methoxy groups [δH 3.79/δC 55.4 87 
and δH 3.53/δC 71.1], a ‒CH2CH(O)C(O)(CH3)2 moiety [δH 4.21 (1H, d, J = 4.7 Hz, H-17)/δC 88 
81.5, 2.33 (1H, dd, J = 13.4, 4.7 Hz, H-16a), 2.09 (1H, d, J = 13.4 Hz, H-16b)/δC 33.7, 1.56 89 
(3H, s, H-19)/δC 21.6 and 1.33 (3H, s, H-20)/δC 28.9], and a 1,1-dimethylallyl group [δH 6.12 90 
(1H, dd, J = 17.4, 10.8 Hz, H-12)/δC 150.3, δH 4.80 (1H, dd, J = 17.4, 1.2 Hz, H-13a), δH 4.79 91 
(1H, dd, J = 10.8, 1.2 Hz, H-13b)/δC 107.6, δH 1.54 (3H, s, H3-15)/δC 30.6, and δH 1.51 (3H, 92 
s, H3-14)/δC 28.2]. Several differences were also found between the NMR spectra of 1 and 93 
those of 1-O-methyl-8-methoxy-8,8a-dihydrobractatin. Compound 1 displayed resonances for 94 
an H-bonded hydroxy group at C-1 and a methoxy group at C-3 while the latter compound 95 
had methoxy and hydroxy groups at C-1 and C-3, respectively. While 1-O-methyl-8-96 
methoxy-8,8a-dihydrobractatin has a common prenyl group, ‒CH2CH=C(CH3)2, at C-5 and a 97 
carbonyl functionality at C-6, the prenyl group in 1 has presumably been oxidized to a 1,2-98 
diol and subsequently formed an intramolecular ketal group at C-6. These structural features 99 
were evident from HMBC experiments (Figure 2 and Table S1, Supporting Information) 100 
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which showed cross-peaks of H-17 (δH 4.21) and H-16b  (δH 2.09) with C-5 (δC 89.5) and C-6 101 
(δC 115.3); δH 12.39 (OH-1) with C-1 (δC 162.5), C-2 (δC 93.4), and C-9a (δC 102.1); and 102 
OMe-3 (δH 3.79) with C-3 (δC 168.0). All assignments of the 
1H and 13C spectroscopic data of 103 
1 are summarized in Tables 1 and 2.  104 
In 2014, Boonak and co-workers reported that three natural caged xanthones from the 105 
roots of Cratoxylum formosum ssp. pruniflorum were scalemic mixtures with enantiomeric 106 
ratios ranging from 1.1:1 to 1.9:1.42 Thus, compound 1 was further analyzed by chiral HPLC 107 
which showed peaks for two enantiomers at tR 8 and 15 min in an approximate ratio of 1:2 108 
(Figure S55, Supporting Information). These two enantiomers were separated by semi-109 
preparative chiral HPLC to afford (+)-1 (tR 8 min), []

 +56.3 (c 0.096, CHCl3), and (‒)-1 110 
(tR 15 min), []

 −42.8 (c 0.1, CHCl3). These enantiomers had identical 
1H NMR spectra. 111 
Enantiomer (+)-1 crystallized from MeOH/CH2Cl2 (4:1, v/v) to give a single crystal that was 112 
subjected to X-ray diffraction analysis using Cu Kα radiation to determine its absolute 113 
configuration. Compound (+)-1 formed colorless plate orthorhombic crystals, with a = 114 
9.2535(2) Å, b = 11.5385(3) Å, c = 24.9217(7) Å, α = 90o, β = 90o, γ = 90o, v = 2660.93(12) 115 
Å, and chiral group P212121, z = 4. From the X-ray data analysis (CCDC 1539179), the 116 
absolute configuration of (+)-1 was established as (5S, 6R, 7R, 8R, 8aS, 10aR, 17R, 22S) with 117 
a Flack x-parameter of 0.01(6) (Figure 3).   118 
Thus, the absolute configuration of (‒)-1 was assigned as (5R, 6S, 7S, 8S, 8aR, 10aS, 119 
17S, 22R). The ECD spectrum of compound (+)-1 showed a negative Cotton effect around 120 
233 nm and a positive Cotton effect around 304 nm while the ECD spectrum of compound (‒121 
)-1 displayed Cotton effects of the opposite signs (Figure 4). Thus, compounds (+)-1 and (−)-122 
1 were assigned the names, (+)-doitunggarcinone E and (−)-doitunggarcinone E, respectively. 123 
Compound 2, doitunggarcinone F, was obtained as a white solid with m.p. 202-205 124 
oC. Its molecular formula, C30H38O7, was deduced from ESITOFMS analysis which showed 125 
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an [M+Na]+ ion at m/z 533.2507 (calcd for 533.2515). The UV, IR, and NMR spectroscopic 126 
data (Tables 1, 2, S2 and Figures S9-S15, Supporting Information) of 2 were also similar to 127 
those of 1-O-methyl-8-methoxy-8,8a-dihydrobractatin15 and 1. The only difference between 128 
the former compound and 2 was the positions of the hydroxy and methoxy groups at C-1 and 129 
C-3. Compound 2 had these groups at C-1 and C-3, respectively, the same as found in 130 
compound 1. The C-6 carbonyl carbon (δC 209.2) and the C-5 prenyl group [δH 5.29 (1H, t, J 131 
= 7.8 Hz, H-17)/δC 118.0, δH 2.88 (1H, m, H-16), δH 2.75 (1H, dd, J = 14.0, 9.5 Hz, H-16)/δC 132 
28.0, δH 1.67 (3H, s, H3-20)/δC 26.1 and δH 1.63 (3H, s, H3-19)/δC 18.1] in compound 2 were 133 
clearly evident. Detailed assignments of the 1H and 13C spectroscopic data of 2 are 134 
summarized in Tables 1 and 2.  135 
Compound 2 was further analyzed and separated by chiral HPLC to yield (+)-2 [tR 14 136 
min, []
 +78.5 (c 0.1, CHCl3)] and (−)-2 [tR 20 min, []
‒92.4 (c 0.1, CHCl3)] in an 137 
approximate ratio of 1:2 (Figure S55, Supporting Information). The absolute configurations 138 
of (+)-2 and (−)-2 were established by comparing their ECD spectra (Figure 4) with those of 139 
compounds (+)-1 and (−)-1. The similarity of the ECD spectra of compounds (+)-2 and (+)-1 140 
and those of (‒)-2 and (−)-1 indicating the absolute configuration of (5S, 7R, 8R, 8aS, 10aR, 141 
22R) for (+)-2 and (5R, 7S, 8S, 8aR, 10aR, 22S) for (‒)-2. Compounds (+)-2 and (‒)-2 were 142 
give the names (+)-doitunggarcinone F and (−)-doitunggarcinone F, respectively. 143 
Compound 3 was isolated as a white solid with m.p. 172-174 oC. Its molecular 144 
formula, C30H38O8, was deduced from ESITOFMS analysis which showed an [M+Na]
+ ion at 145 
m/z 549.2460  (calcd for 549.2464). The UV, IR and NMR spectroscopic data of compound 3 146 
(Tables 1, 2, S3 and Figures 17-23, Supporting Information) were similar to those of 2 147 
indicating a caged xanthone core structure. The major differences observed in the 1H and 13C 148 
NMR spectroscopic data (Tables 1 and 2) of 2 and 3 were that compound 3 displayed 149 
resonances for an (E)-3-hydroxy-3-methyl-1-butenyl  moiety [δH 6.18 (1H, d, J = 16.0 Hz, H-150 
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17)/δC 144.6, δH 5.75 (1H, d, J = 16.0 Hz, H-16)/δC 117.7, δH 1.36 (3H, s, H3-20)/δC 29.9 and 151 
δH 1.35 (3H, s, H3-19)/δC 29.5] instead of resonances for a prenyl group evident in the 
1H 152 
NMR spectroscopic data of 2. This structure was confirmed by the following HMBC cross-153 
peaks: H-16 (δH 5.75) with C-5 (δC 88.1), C-6 (δC 208.6), C-17 (δC 144.6) and C-18 (δC 71.1); 154 
H-17 (δH 6.18) with C-5 (δC 88.1), C-16 (δC 117.7), and C-17 (δC 144.6); and Me-19 (δH 155 
1.35)/Me-20 (δH 1.36) with C-18 (δC 71.1) and C-17 (δC 144.6) (Figure 2 and Table S3, 156 
Supporting Information). Compound 3 was resolved by chiral HPLC yielding (+)-3 [tR 17 157 
min, []
 +39.3 (c 0.1, CHCl3)] and (−)-3 [tR 30 min, []
‒48.5 (c 0.1, CHCl3)] in a ratio 158 
of 1.2:2. The absolute configurations of compounds (+)-3 (5S, 7R, 8R, 8aS, 10aR, 22R) and 159 
(−)-3 (5R, 7S, 8S, 8aR, 10aR, 22S) were established by comparison of their ECD spectra 160 
(Figure 4) with those of (+)-2 and (−)-2, respectively. Compounds (+)-3 and (−)-3 were 161 
named, (+)-doitunggarcinone G and (−)-doitunggarcinone G, respectively. 162 
Compound 4, a white solid with m.p. 162-163 oC, showed an [M+Na]+ ion at m/z 163 
567.2571  (calcd for 567.2570) in ESITOFMS corresponding to a molecular formula of 164 
C30H40O9. The UV, IR, and NMR spectroscopic data of 4 (Tables 1, 2, S4 and Figures 25-31, 165 
Supporting Information) were similar to those of compound 2 except that the ∆17(18) double 166 
bond in 2 changed to a 3-methylbutan-2,3-diol moiety in 4 [δH 4.11 (1H, dd, J = 9.1, 7.1 Hz, 167 
H-17)/δC 82.4, δH 2.80 (1H, dd, J = 15.0, 9.1 Hz, H-16a), δH 1.99 (1H, dd, J = 15.0, 7.1 Hz, 168 
H-16b)/δC 28.9, δH 1.33 (3H, s, H-19)/δC 28.5 and δH 1.12 (3H, s, H-20)/δC 24.2]. This 169 
structure was further supported by the following HMBC cross-peaks: H-16a (δH 2.80) with C-170 
5 (δC 92.6), C-10a (δC 88.6), C-17 (δC 82.4), and C-18 (δC 70.1); and Me-19 (δH 1.33)/Me-20 171 
(δH 1.12) with C-17 (δC 82.4) and C-18 (δC 70.1) (Figure 2 and Table S4, Supporting 172 
Information). The NOESY spectrum showed cross peaks between H-8a/H-16 and between H-8/H-173 
21/H-22 which supported the caged bridge-head orientation. Resolution of compound 4 by 174 
chiral HPLC gave (+)-4 [tR 9 min, []




75.6 (c 0.1, CHCl3)] in a ratio of 2:1.6 (Figure S55, Supporting Information). The absolute 176 
configuration of compound (+)-4 was identified as (5S, 7R, 8R, 8aS, 10aR, 22R) since its 177 
ECD spectrum (Figure 4) was similar to those of compounds (+)-1, (+)-2, and (+)-3 while the 178 
configuration of compound (−)-4 was identified as (5R, 7S, 8S, 8aR, 10aR, 22S) from its ECD 179 
spectrum (Figure 4) which displayed Cotton effects of the opposite sign to those of (+)-4 and 180 
similar to those of compounds (−)-1, (−)-2, and (−)-3. Because of an insufficient quantity of 181 
(+)-4 or (−)-4, the absolute configurations of these compounds at C-17 could not be 182 
determined. Compounds (+)-4 and (−)-4 were assigned the names, (+)-doitunggarcinone H 183 
and (−)-doitunggarcinone H, respectively. 184 
Compound 5 was isolated as a white solid with m.p. 158-162 oC. Its molecular 185 
formula, C30H38O8, was established from ESITOFMS analysis which showed an [M+Na]
+ ion 186 
at m/z 549.2466  (calcd for 549.2464). Its UV, IR, and NMR spectroscopic data (Tables 1, 2, 187 
S5 and Figures 33-39, Supporting Information) were similar to those of 4 except compound 5 188 
had formally been dehydrated at C-18/C-19 to generate a 2-hydroxy-3-methylbut-3-enyl unit 189 
[δH 5.08 (1H, s, H-19a), δH 4.88 (1H, s, H-19b)/δC 112.1, δH 4.53 (1H, t, J = 8.1 Hz, H-17)/δC 190 
79.3, δH 2.76 (1H, dd, J = 13.9, 6.2 Hz, H-16a), δH 2.10 (1H, m, H-16b)/δC 32.5, and δH 1.80 191 
(3H, s, H-20)/δC 17.4] instead of the 3-methylbutan-2,3-diol group in 4. Full assignments of 192 
the NMR spectroscopic data of 5 are summarized in Tables 1 and 2. Resolution of 5 by chiral 193 
HPLC afforded (+)-5 [tR 6 min,	[]
 +55.1 (c 0.1, CHCl3)] and (−)-5 (tR 8 min, []
‒65.2 194 
(c 0.1, CHCl3)] in a ratio of ca 2:1.6 (Figure S55, Supporting Information). The absolute 195 
configuration of (5S, 7R, 8R, 8aS, 10aR, 22R) for (+)-5 and (5R, 7S, 8S, 8aR, 10aS, 22S) for 196 
(‒)-5 were established via the comparison of their ECD spectra (Figure 4) with those of (+)-197 
1−(+)-4 and (‒)-1−(‒)-4. Similar to 4, the absolute configuration of compounds (+)-5 or (−)-5 198 
at C-17 could not be determined due to the insufficient quantities of these samples. 199 
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Compounds (+)-5 and (‒)-5 were assigned the trivial names (+)-doitunggarcinone I and (−)-200 
doitunggarcinone I, respectively.   201 
Compound 6 was isolated as a white solid with m.p. 175-178 °C. The ESITOFMS 202 
displayed an [M+Na]+ ion at m/z 535.2313 (calcd for 535.2308) indicating the molecular 203 
formula of C29H36O8. The UV, IR, and NMR spectroscopic data (Tables 1, 2, S6 and Figures 204 
41-47, Supporting Information) were similar to those of 3. The main structural differences 205 
involved the substituents at C-3 and C-4 of the aromatic moiety. Compound 6 displayed 206 
resonances for a 2,3,3-trimethyldihydrofuran unit [δH 4.37 (1H, m, H-12)/δC 90.9, δH 1.41 207 
(3H, s, H3-14)/δC 25.7, δH 1.37 (3H, d, J = 7.2 Hz, H3-13)/δC 14.3, and δH 1.25 (3H, s, H3-208 
15)/δC 21.8].  209 
Compound 6 was resolved by chiral HPLC to afford compounds (+)-6 [tR 30 min, 210 
[]
 +82.3 (c 0.1, CHCl3)] and (−)-6 [tR 34 min,	[]
‒64.6 (c 0.1, CHCl3)] in a ratio of 211 
1.2:2 (Figure S55, Supporting Information). The (5S, 7R, 8R, 8aS, 10aR, 22R) absolute 212 
configuration of (+)-6 and (5R, 7S, 8S, 8aR, 10aR, 22S) of (−)-6 were established by 213 
comparison of their ECD spectra with those of (+)-1−(+)-5 and (−)-1−(−)-5, respectively 214 
(Figure 4). Compounds (+)-6 and (−)-6 were named as (+)-doitunggarcinone J and (−)-215 
doitunggarcinone J, respectively. The C-12 hydrogen in these compounds was too remote 216 
from the caged xanthone protons to permit definition of the absolute configuration at C-12 217 
using NOESY data.   218 
Compound 7 was also obtained as a white solid (m.p. 188-191 oC), with the molecular 219 
formula of C28H32O6 determined from an [M+Na]
+ ion at m/z 487.2092  (calcd for 487.2097) 220 
in ESITOFMS. The UV, IR, as well as NMR spectroscopic data (Tables 1, 2, S7 and Figures 221 
49-53, Supporting Information) of 7 were similar to those of cochinchinoxanthone isolated 222 
from Cratoxylum cochinchinense stems.43 However, compound 7 showed additional 223 
resonances for a prenyloxy group [δH 4.57 (2H, m, H-11)/δC 65.2, δH 5.47 (1H, m, H-12)/δC 224 
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118.5, δH 1.83 (3H, s, H3-14)/δC 25.4 and δH 1.78 (3H, s, H3-15)/δC 17.9] located at C-3 225 
instead of the hydroxy group in cochinchinoxanthone. The HMBC cross-peaks of H-2 (δH 226 
6.11), H-4 (δH 6.08) and H-11 (δH 4.57) with C-3 (δC 167.6) supported the above structural 227 
feature (Figure 2 and Table S7, Supporting Information). Full details of the NMR 228 
spectroscopic data are summarized in Tables 1 and 2. Compound 7 was shown to be a 1:2 229 
mixture of enantiomers by analytical chiral HPLC analysis but was not resolved because of 230 
the paucity of material. Compound 7 was named doitunggarcinone K. 231 
The isolation of compounds 1-7 as scalemic mixtures may suggest that they have been 232 
synthesized via a series of non-enzymatic and enzymatic processes. Compounds 1-7 are 233 
presumably produced biosynthetically from 14 as shown in Scheme 1. The caged core 234 
structure could be obtained from xanthone 14 via O-prenylation at C-5 and C-6 (intermediate 235 
14.1), followed by a Claisen rearrangement (intermediate 14.2) and then an intramolecular 236 
Diels-Alder reaction (intermediate 14.3).44 A further Claisen rearrangement of intermediate 237 
14.3 could produce compound 7 whereas O-methylation at C-3 would produce intermediate 238 
14.4. Compounds 1-6 could then be obtained from intermediate 14.4 by a series of 239 
oxidation/dehydration processes. Using (+)-2 as an example, a diastereoselective 1,2-240 
dihydroxylation reaction of the ∆17(18) double bond of (+)-2 would produce (+)-4 which upon 241 
intramolecular ketalization with the C-6 carbonyl group would give (+)-1. If this were the 242 
case then (+)-4 should have a (17R) configuration, the same as (+)-1 (from X-ray analysis). 243 
Compounds (+)-3 and (+)-5 could also arise from dehydration reactions of (+)-4 and (+)-5, 244 
while (+)-5 could arise directly from (+)-2 via an allylic oxidation reaction with concomitant 245 
transposition of the double bond. Cyclization of the HO-3 onto the C-4 olefinic moiety, with 246 
concomitant or prior loss of the methyl group from the MeO-3, would give the dihydrofuran 247 
moiety of (+)-6. 248 
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All compounds were evaluated for their cytotoxicities against a colon cancer cell line. 249 
Only compounds (‒)-6 and 7 showed cytotoxicities with IC50 values of 14.23 and 23.95 µM, 250 
respectively (doxorubicin as positive control had an IC50 value of 9.74 µM). It is interesting 251 
to note that only the levorotatory enantiomer of (‒)-6 had cytotoxicity while its enantiomer 252 
was inactive.      253 
Prenylated caged xanthones have been isolated and identified from many species of 254 
the Garcinia (Clusiaceae).11-21,32,43,45-53 A few of these compounds have also been found in 255 
another genus of Clusiaceae, Cratoxylum cochinchinesis54,55 and C. formosum ssp. 256 
pruniflorum.42 Caged xanthones containing a ∆8(8a) double bond, a carbonyl group at C-6, and 257 
the caged bridge-head at C-5/C-7/C-10a are commonly found in natural products.11,13-258 
19,21,32,42, 43, 45-55 while the differences of caged bridge-head (C-6/C-7/C-10a) and carbonyl 259 
group (C-5) are called neocaged xanthones which are rare compounds.12,15,20,21,32,42 In 260 
addition, 8,8a dihydro caged xanthones like compounds 1-6, are rarely found in Nature.11,14-261 
16,49-53 In this study, we have isolated six new scalemic dihydrocaged xanthones, 262 
doitunggarcinones E-J, from the stem bark extracts of G. propinqua that resolved by chiral 263 
HPLC. Additionally a new caged xanthone, doitunggarcinone K, was also isolated as a 264 
scalemic mixture. All compounds were evaluated for their cytotoxicities against a colon 265 
cancer cell line but only (‒)-doitunggarcinone J and doitunggarcinone K, exhibited moderate 266 
cytotoxicities.      267 
EXPERIMENTAL SECTION 268 
General Experimental Procedures. Melting points were measured on a Buchi 269 
melting point B-540 visual thermometer. The optical rotations were measured with a 270 
Bellingham & Stanley APD440 polarimeter. The UV spectra were recorded with a Perkin-271 
Elmer UV-Vis or Varian Cary 5000 UV-Vis-NIR spectrophotometers. Infrared (IR) spectra 272 
were recorded on a Perkin Elmer FTS FT-IR or Perkin Elmer Frontier Optica FT-IR 273 
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spectrophotometers. ECD spectra were recorded on a JASCO J-815 spectrometer. The 1D 274 
and 2D NMR spectra were recorded on a 400 MHz Bruker  FT-NMR Ultra Shield and 600 275 
MHz Bruker AV-600 spectrometers in CDCl3 (δH 7.24 and δC 77.0) and/or acetone-d6 (δH 276 
2.05 and δC (CO) 206.2 and (CH3) 30.6), with TMS as the internal standard. Chemical shifts 277 
are reported in parts per million (δ), and coupling constants (J) are expressed in hertz. ESI-278 
QIT-MS spectra were measured on a Bruker-Hewlett-Packard 1100 Esquire-LC system mass 279 
spectrometer. HPLC was performed on a Waters 515 HPLC pump system liquid 280 
chromatography using the following columns: RP C18 CSC-Inertsil 150A/ODS-2 column (25 281 
× 0.94 cm) and a CHIRALCEL OD-H column (4.6 × 250 mm). Quick column 282 
chromatography (QCC) and column chromatography (CC) were carried out on silica gel 60 H 283 
(5-40 µm, SiliCycle® Inc.) and silica gel 100 (63-200 µm, SiliCycle® Inc.), respectively. 284 
Sephadex LH-20 was also used for CC. Precoated plates of silica gel 60 F254 were used for 285 
analytical purposes. 286 
Plant Material. The stem bark of G. propinqua was collected from Doi Tung, Chiang 287 
Rai Province, Thailand in September 2011, The plant was identified by Mr. Matin Van de 288 
Bult (Doi Tung Development Project, Chiang Rai, Thailand), and the specimen (MFU-289 
NPR0090) was deposited at the Natural Products Research Laboratory, School of Science, 290 
Mae Fah Luang University. 291 
Extraction and Isolation. Chopped and air-dried stem bark of G. propinqua (6.0 kg) 292 
was extracted with MeOH (2 × 10 L) at room temperature. The extract was evaporated under 293 
reduced pressure to give a brown gum (150 g) which was dissolved in H2O and successively 294 
partitioned with CH2Cl2 and EtOAc. The CH2Cl2 and EtOAc extracts were combined (113 g) 295 
and subjected to QCC on silica gel using a gradient of hexanes and EtOAc (100% hexanes to 296 
100% EtOAc) to afford compound 8 (36 mg) and 10 fractions (J1-J10). Fraction J2 (200 mg) 297 
was purified by CC (1:9 EtOAc/hexanes) to give compound 11 (3.2 mg). Fraction J3 (250 298 
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mg) was separated by CC 9 (1:9 acetone/hexanes) to obtain six subfractions (3J1-3J6). 299 
Subfraction 3J1 (50 mg) was further separated by CC (3:7 CH2Cl2/hexanes) to afford two 300 
subfractions (3J1A and 3J1B). Subfraction 3J1B (25 mg) was further isolated by HPLC using 301 
RP C18 CSC-Inertsil 150A/ODS-2 column, flow rate 2 mL/min, 4:1 MeOH/H2O (acidified 302 
with 0.05% TFA) to give compound 2 (15 mg, tR = 20 min). Subfraction 3J2 (20 mg) was 303 
purified by RP C18 HPLC (flow rate 2 mL/min, 4:1 MeCN-H2O (acidified with 0.05% TFA) 304 
yielding compound 7 (2.2 mg, tR = 25 min). Subfraction 3J6 (150 mg) was further purified by 305 
CC (1:9 acetone/hexanes) to give six subfractions (3J6-A-3J6F). Subfraction 3J6-E (110 mg) 306 
was further separated by Sephadex LH-20 (8:2 MeOH/CH2Cl2) to afford four subfractions 307 
(3J6-E1-3J6-E4). Subfraction 3J6-E2 (80 mg) was washed with hexanes and further purified 308 
by RP C18 HPLC (flow rate 2 mL/min, 4:1 MeCN-H2O (acidified with 0.05% TFA) to afford 309 
compound 1 (13 mg, tR = 31 min). The hexanes washing from subfraction 3J6-E2 (60 mg) 310 
was purified RP C18 HPLC (flow rate 2 mL/min, 4:1 MeCN/H2O (acidified with 0.05% TFA) 311 
to give compounds 3 (14.0 mg, tR 14 min), 4 (7.2 mg, tR 17 min), 5 (10.3 mg, tR 21 min), and 312 
6 (10.5 mg, tR 12 min). Fraction J4 (85 mg) was further separated by CC (1:9 313 
acetone/hexanes) to yield compounds 9 (11.5 mg) and 10 (3.6 mg). Purification of fraction J5 314 
(15 mg) by PLC (3:7 CH2Cl2/hexanes) gave compounds 15 (2.9 mg), 16 (3.0 mg), and 17 315 
(4.5 mg). Fraction J6 (120 mg) was further separated by CC (1:4 acetone/hexanes) to yield 316 
compounds 12 (90.7 mg) and 13 (11.5 mg). Compound 14 (5.9 mg) was obtained from 317 
subfraction J8 (200 mg) by CC (1:19 EtOAc/hexanes).  318 
Doitunggarcinone E (1). White solid, m.p. 183-185 oC; UV (MeOH) λmax (log ε) 219 319 
(4.04), 232 (3.89), 239 (3.72), 295 (3.91) and 342 (3.24) nm; IR (neat) νmax 3415 and 1639 320 
cm-1; 1H NMR (CDCl3, 600 MHz) δand 
13C NMR data, see Tables 1 and 2; ESITOFMS m/z 321 
527.2643 [M+H]+ (calcd for C30H38O8, 527.2645). 322 
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Chiral HPLC Separation and ECD Spectroscopic Data (+)-1 and (‒)-1: Separation of 323 
the two enantiomers of 1 (13.0 mg) was performed by semi-preparative HPLC on a chiral 324 
column (CHIRALCEL OD-H column, flow rate 2 mL/min, 49:1 n-hexane–iPrOH). 325 
Compound (+)-1 (tR = 8 min) [(4.8 mg), []
 +56.3 (c 0.1, CHCl3)]; ECD (c 9.510
-5 M, 326 
MeOH) λmax (∆ε); 230 (−1.0710
2), 233 (−1.05102) and 304 (+0.6102) nm] and (‒)-1 (tR 327 
= 15 mim) [(6.5 mg), []
 −42.8 (c 0.1, CHCl3)]; ECD (c 9.710
-5 M, MeOH) λmax (∆ε); 328 
233 (+1.04102), 238 (+0.96102) and 302 (−0.96102) nm] were obtained.  329 
Doitunggarcinone F (2). White solid, m.p. 202-205 oC; UV (MeOH) λmax (log ε) 218 330 
(4.11), 232 (3.91), 240 (3.67), 295 (3.98) and 341 (3.26) nm; IR (neat) νmax 3414, 1710, 1636 331 
cm-1; 1H NMR (CDCl3, 600 MHz) and 
13C NMR data, see Tables 1 and 2; ESITOFMS m/z 332 
533.2507 [M+Na]+ (calcd for C30H38O7, 533.2515). 333 
Chiral HPLC Separation and ECD Spectroscopic Data (+)-2 and (‒)-2: Separation of 334 
the two enantiomers of 2 (15.0 mg) was performed by the method described for 1, to give 335 
compound (+)-2 (tR = 14 min) [(5.5 mg), []
 +78.5 (c 0.1, CHCl3)]; ECD (c 7.810
-5 M, 336 
MeOH) λmax (∆ε); 236 (−1.4410
2) and 303 (+1.96102) nm] and (‒)-2 (tR = 20 mim) [(5.2 337 
mg), []
 −92.4 (c 0.1, CHCl3)]; ECD (c 6.910
-5 M, MeOH) λmax (∆ε); 236 (+1.7610
2) 338 
and 303 (−2.37102) nm].  339 
Doitunggarcinone G (3). White solid, m.p. 172-174oC; UV (MeOH) λmax (log ε) 218 340 
(4.00), 230 (3.84), 240 (3.60), 295 (3.86) and 340 (3.20) nm; IR (neat) νmax 3465, 1741, 1634 341 
cm-1; 1H NMR (CDCl3, 600 MHz) and 
13C NMR data, see Tables 1 and 2; ESITOFMS m/z 342 
549.2460 [M+Na]+ (calcd for C30H38O8, 549.2464). 343 
Chiral HPLC Separation and ECD Spectroscopic Data (+)-3 and (‒)-3: Separation of 344 
the two enantiomers of 3 (14.0 mg) was performed by the method described for 1, yielding 345 
compound (+)-3 (tR = 17 min) [(6.2 mg), []
 +39.3 (c 0.1, CHCl3)]; ECD (c 7.210
-5 M, 346 
MeOH) λmax (∆ε); 235 (−1.4410
2), 241 (−1.17102) and 305 (+1.93102) nm] and (‒)-3 347 
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(tR = 30 mim) [(5.1 mg), []
 −48.5 (c 0.1, CHCl3)]; ECD (c 7.210
-5 M, MeOH) λmax (∆ε); 348 
236 (+1.07102), 240 (+1.18102) and 305 (−1.66102) nm].  349 
Doitunggarcinone H (4). White solid, m.p. 162-164oC; UV (MeOH) λmax (log ε) 219 350 
(4.04), 232 (3.88), 240 (3.89), 294 (3.92) and 340 (3.25) nm; IR (neat) νmax 3407, 1714, 1636 351 
cm-1; 1H NMR (CDCl3, 600 MHz) and 
13C NMR data, see Tables 1 and 2; ESITOFMS m/z 352 
567.2571 [M+Na]+ (calcd for C30H40O9, 567.2570). 353 
Chiral HPLC Separation and ECD Spectroscopic Data (+)-4 and (‒)-4: Separation of 354 
the two enantiomers of 4 (7.2 mg) was performed by the method described for 1, yielding 355 
compound (+)-4 (tR = 9 min) [(3.8 mg), []
 +90.7 (c 0.1, CHCl3)]; ECD (c 7.710
-5 M, 356 
MeOH) λmax (∆ε); 232 (−1.2410
2), 239 (−0.95102) and 301 (+0.87102) nm] and (‒)-4 357 
(tR = 11 mim) [(3.2 mg), []
 −75.6 (c 0.1, CHCl3)]; ECD (c 8.310
-5 M, MeOH) λmax (∆ε); 358 
232 (+0.92102), 238 (+0.77102) and 301 (−0.79102) nm].  359 
Doitunggarcinone I (5). White solid, m.p. 158-162oC; UV (MeOH) λmax (log ε) 219 360 
(4.10), 235 (3.88), 240 (3.73), 294 (3.96) and 342 (3.13) nm; IR (neat) νmax 3465, 1737, 1637 361 
cm-1; 1H NMR (CDCl3, 600 MHz) and 
13C NMR data, see Tables 1 and 2; ESITOFMS m/z 362 
549.2466 [M+Na]+ (calcd for C30H38O8, 549.2464). 363 
Chiral HPLC Separation and ECD Spectroscopic Data (+)-5 and (‒)-5: Separation of 364 
the two enantiomers of 5 (10.3 mg) was performed by the method described for 1, yielding 365 
compound (+)-5 (tR = 6 min) [(4.5 mg), []
 +55.1 (c 0.1, CHCl3)]; ECD (c 8.910
-5 M, 366 
MeOH) λmax (∆ε); 233 (−0.8110
2), 240 (−1.02102) and 298 (+0.89102) nm] and (‒)-5 367 
(tR = 8 mim) [(4.0 mg), []
 −65.2 (c 0.1, CHCl3)]; ECD (c 9.510
-5 M, MeOH) λmax (∆ε); 368 
231 (+0.28102), 241 (+0.61102) and 302 (−0.73102) nm]. 369 
Doitunggarcinone J (6). White solid, m.p. 175-178oC; UV (MeOH) λmax (log ε) 216 370 
(4.02), 233 (3.72), 242 (3.57), 296 (3.78) and 335 (3.31) nm; IR (neat) νmax 3479, 1741, 1637 371 
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cm-1; 1H NMR (CDCl3, 600 MHz) and 
13C NMR data, see Tables 1 and 2; ESITOFMS m/z 372 
535.2313 [M+Na]+ (calcd for C29H36O8, 535.2308). 373 
Chiral HPLC Separation and ECD Spectroscopic Data (+)-6 and (‒)-6: Separation of 374 
the two enantiomers of 6 (10.5 mg) was performed by the method described for 1, yielding 375 
compound (+)-6 (tR = 30 min) [(4.7 mg), []
 +82.3 (c 0.1, CHCl3)]; ECD (c 8.010
-5 M, 376 
MeOH) λmax (∆ε); 233 (−0.3810
2), 243 (−0.50102) and 304 (+0.82102) nm] and (‒)-6 377 
(tR = 34 mim) [(5.3 mg), []
 −64.6 (c 0.1, CHCl3)]; ECD (c 7.610
-5 M, MeOH) λmax (∆ε); 378 
236 (+0.67102), 245 (+0.66102) and 301 (−0.90102) nm]. 379 
Doitunggarcinone K (7). White solid, m.p. 188-191 oC; [(2.2 mg), []
 ‒24.5 (c 380 
0.02, CHCl3)]; UV (MeOH) λmax (log ε) 214 (4.14), 227 (3.92), 246 (3.47), 322 (3.77) and 381 
350 (3.69) nm; IR (neat) νmax 3447, 1737, 1640 cm
-1; 1H NMR (CDCl3, 600 MHz) and 
13C 382 
NMR data, see Tables 1 and 2; ESITOFMS m/z 487.2092 [M+Na]+ (calcd for C28H32O6, 383 
487.2097).  384 
Chiral HPLC Analysis of 7: Compound 7 was analyzed by analytical chiral HPLC 385 
using the conditions described for 1, to give peaks for two enantiomers at the retention times 386 
of tR 9 min and tR 12 min in an approximate ratio of 1:2. Lack of material precluded their 387 
quantitative resolution.  388 
X-ray Crystallographic Analysis of Compound (+)-1 389 
Single-crystal X-ray diffraction data was collected on a Bruker APEX DUO 390 
diffractometer with cross-coupled multilayer optics Cu-Kα radiation. Data were corrected for 391 
absorption effects using the multi-scan technique (SADABS). The structure was solved by 392 
direct methods. 393 
Single-crystal X-ray Data for (+)-1: Colorless plate crystal of C30H38O8, M = 394 
526.60, crystal system orthorhombic with a = 9.2535(2) Å, b = 11.5385(3) Å, c = 24.9217(7) 395 
Å, α = 90o, β = 90o, γ = 90o, v = 2660.93(12) Å, and chiral group P212121, z = 4. The X-ray 396 
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diffraction analysis using Cu-Ka radiation values were 7.75 cm-1, 23279 reflections 397 
measured, 6495 independent reflections (Rint = 0.029). Final R indices:  R1 [I > 0.00σ (I)] = 398 
0.030 and wR2 = 0.077. The standard deviation of an observation of unit weight was 1.03. 399 
The absolute configurations of (+)-1 was assigned as (5S, 6R, 7R, 8S, 8aS, 10as, 17R, 22S) 400 
with a Flack x-parameter of 0.01(6). Crystallographic data for compound (+)-1 have been 401 
deposited with the Cambridge Crystallographic Data Center (CCDC 1539179).  These data 402 
can be obtained free of charge from the Cambridge Crystallographic Data Centre via 403 
www.ccdc.cam.ac.uk/data_request/cif. 404 
Cytotoxic Assay 405 
HCT116 colon cancer cells (1 × 104 cells/well) were cultured in a 96 well plate and 406 
allowed to adhere for 24 h at 37 ºC. The cells were treated with compounds (10 µM or 407 
µg/mL) in DMEM medium for 24 h. The medium was removed and fresh DMEM containing 408 
0.5 mg/mL of MTT solution was added to each well for 2 h. After that, the medium was 409 
discarded by aspirator. The violet formazan crystals in the viable cells were dissolved in 100 410 
µL of DMSO. The absorbance of each well were read at a wavelength of 570 nm using a 411 
microplate reader. Doxorubicin was used as a positive control with an IC50 value of 9.74 µM. 412 





 × 100 413 
                    % Cytotoxicity = 100 ‒ % cell viability 414 
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Scheme 1. Putative biosynthesis pathway to compounds 1-7. 
27 
 
Table 1. 1H NMR Spectroscopic Data (600 MHz) of Compounds 1– 7 in CDCl3. 
Position 1 2 3 4 5 6 7 
1 - - - - - - - 
2 6.08, s 6.11, s 6.11, s 6.10, s 6.12, s 6.07, s 6.11, brs 
3 - - - - - - - 
4 - - - - - - 6.08, brs 
4a - - - - - - - 
5 - - - - - - - 
6 - - - - - - - 
7 2.41, m 2.81, m 2.90, m 2.20, m 2.46, m 2.95, m 3.52, m 
8 4.00, dd (4.4, 2.6) 4.34, m 4.40, d (3.3) 4.13, m 4.13, m 4.46, m 7.44, d (4.9) 
8a 3.01, d (4.4) 3.31, m 3.18, m 3.21, d (3.5) 3.03, m 3.16, m - 
9 - - - - - - - 
9a - - - - - - - 
10a - - - - - - - 
11 - - - - - - 4.57, m 
12 6.12, dd (17.4, 10.8) 6.16, dd (17.2, 10.8) 6.09, dd (17.6, 10.9) 6.13, dd (17.5, 10.6) 6.16, dd (17.2, 10.8) 4.37, m 5.47, m 
13 4.80, dd (17.4, 1.2) 4.80, d (17.2) 4.80, d (17.6) 4.82, d (17.5) 4.82, d (17.2) 1.37, d (7.2)  
 4.79, dd (10.8, 1.2) 4.78, d (10.8) 4.78, d (10.9) 4.81, d (10.6) 4.81, d (10.8)   
14 1.54, s 1.55, s 1.54, s 1.53, s 1.57, s 1.41, s 1.83, s 
15 1.51, s 1.62, s 1.51, s 1.51, s 1.53, s 1.25, s 1.78, s 
16 2.33, dd (13.4, 4.7) 2.88, m 5.75, d (16.0) 2.80, dd (15.0, 9.1) 2.76, dd (13.9, 6.2) 5.72, d (15.8) 2.63, m 
 2.09, d (13.4) 2.75, dd (14.0, 9.5)  1.99, dd (15.0,7.1) 2.10, m   
17 4.21, d (4.7) 5.29, t (7.8) 6.18, d (16.0) 4.11, dd (7.1, 9.1) 4.53, t (8.1) 6.27, d (15.8) 4.47, m 
18 - - - - - - - 
19 1.56, s 1.63, s 1.35, s 1.33, s 5.08, s 1.36, s 1.42, s 
     4.88, s   
20 1.33, s 1.67, s 1.36, s 1.12, s 1.80, s 1.35, s 1.14, s 
21 2.26, dd (15.2, 5.2) 1.96, dd (14.4, 5.4) 1.97, dd (14.6, 5.8)  2.17, dd (15.3, 5.9) 2.18, m 2.02, m 2.35, d (15.5) 
 1.41, dd (15.2, 10.2) 1.39, m 1.43, m 1.40, m 1.27, m 1.49, m 1.33, m 
22 2.22, d (10.2) 2.48, d (8.5) 2.51, d (8.3) 2.53, dd (4.6, 3.5) 2.22, m 2.62, m 2.44, d (8.8) 
23 - - - - - - - 
24 1.26, s 1.11, s 1.42, s 1.40, s 1.40, s 1.22, s 1.32, s 
25 1.33, s 1.36, s 1.16, s 1.41, s 1.39, s 1.51, s 1.70, s 
OH-1 12.39, s 12.36, s 12.24, s 12.19, s 12.31, s 12.00, s 12.47, s 
OMe-3 3.79, s 3.79, s 3.79, s 3.81, s 3.81, s   
OMe-8 3.53, s 3.30, s 3.36, s 3.45, s 3.43, s 3.36, s  
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Table 2. 13C NMR Spectroscopic Data (150 MHz) of Compounds 1 – 7 in CDCl3.  
Position 1 2 3 4 5 6 7 
1 162.5 163.0 162.8 162.5 162.5 164.3 164.9 
2 93.4 94.0 93.8 93.7 93.7 92.3 95.7 
3 168.0 168.1 168.1 168.0 168.0 169.6 167.6 
4 114.0 115.2 115.1 114.2 114.3 114.2 94.7 
4a 157.0 157.0 156.9 156.3 156.5 158.0 160.7 
5 89.5 86.9 88.1 92.6 92.0 87.7 84.2 
6 115.3 209.2 208.6 207.0 207.2 208.4 202.9 
7 31.6 44.8 44.3 41.7 34.7 44.1 46.5 
8 79.3 74.9 74.2 75.6 75.2 73.4 133.7 
8a 48.6 47.4 47.5 47.8 49.0 47.6 135.4 
9 196.1 195.0 194.5 194.7 195.0 192.6 179.3 
9a 102.1 102.6 102.5 105.0 102.2 102.3 101.1 
10a 88.5 88.5 89.3 88.6 87.7 88.6 90.0 
11 41.2 41.3 41.3 41.1 41.0 43.4 65.2 
12 150.3 150.2 150.0 149.9 150.1 90.9 118.5 
13 107.5 107.8 107.7 107.5 107.6 14.3 139.4 
14 30.6 30.8 31.1 30.0 30.5 25.7 25.4 
15 28.2 28.8 28.7 28.4 28.5 21.8 17.9 
16 33.7 28.0 117.7 28.9 32.5 117.3 28.8 
17 81.5 118.0 144.6 82.4 79.3 144.8 118.3 
18 85.8 133.9 71.1 70.1 144.7 71.2 135.2 
19 21.6 18.1 29.5 28.5 112.1 29.7 25.2 
20 28.9 26.1 29.9 24.2 17.4 30.0 16.7 
21 25.1 20.3 20.0 23.6 24.2 20.0 24.9 
22 43.2 44.0 43.2 34.0 41.8 43.9 48.5 
23 79.5 81.1 82.1 83.4 83.2 82.0 83.3 
24 27.2 27.5 27.3 26.2 26.6 30.927.4 28.8 
25 30.2 30.5 30.5 30.5 30.4 27.430.9 29.9 
OMe-3 55.4 55.4 55.4 55.4 55.4  - 
OMe-8 57.1 55.7 55.8 55.8 56.0 55.9 - 
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